Why the study?
Is sarcopenic obesity associated with a higher prevalence of historical and contemporaneous cardiometabolic risk factors compared to other body composition phenotypes?
Cohort (n=1,019)
Is sarcopenic obesity associated with a higher prevalence of historical and contemporaneous cardiometabolic risk factors compared to other body composition phenotypes?
Older adults with sarcopenic obesity exhibit a more adverse midlife cardiometabolic risk profile, particularly a higher prevalence of diabetes 10 years prior, highlighting the need for early risk factor identification.
Answers are grounded in this paper and cite their sources.
May support earlier cardiometabolic screening in older adults; leaves open causal direction and need for prospective trials.
OBJECTIVE: Midlife and contemporaneous cardiometabolic risk factors associated with sarcopenic obesity were examined. METHODS: Utilizing BMI and sex-specific 24-h urinary creatinine excretion, 1,019 participants from the Framingham cohorts were categorized as non-sarcopenia non-obese (NSNO), non-obese sarcopenia, non-sarcopenic obesity, and sarcopenic obesity. Cardiometabolic risk factors were quantified by standard laboratory assessment cross-sectionally and 10, 20, and 30 years before sarcopenic obesity assessment. RESULTS: NSNO, sarcopenia, obesity, and sarcopenic obesity accounted for 30.0%, 39.6%, 20.0%, and 10.4% of study participants, respectively. Cross-sectionally, participants with sarcopenic obesity had a higher proportion of hypertension, metabolic syndrome, and type 2 diabetes than those with NSNO or sarcopenia (all P < 0.03). Similar patterns were observed retrospectively at 10, 20, and 30 years. Compared with NSNO or sarcopenia, sarcopenic obesity was associated with a higher prevalence of type 2 diabetes at 10 years and hypertension and metabolic syndrome at all three time points before baseline (all P < 0.03). Individuals with sarcopenic obesity had more type 2 diabetes than those with obesity alone at baseline and 10 years prior (all P < 0.001). CONCLUSIONS: Older adults with sarcopenic obesity had more adverse midlife cardiometabolic risks, particularly diabetes 10 years earlier, which suggests the importance of early identification of risk factors associated with sarcopenic obesity.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2016) conducted a cohort in Sarcopenic obesity (n=1,019). Sarcopenic obesity vs. Non-sarcopenia non-obese (NSNO) or sarcopenia alone was evaluated on Cardiometabolic risk factors (hypertension, metabolic syndrome, and type 2 diabetes) (p=<0.03).
Synapse has enriched 10 related papers. Consider them for comparative context: